Instituto de Oftalmología Fundación Conde de Valenciana clinical trials
Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Mexico register with Instituto de Oftalmología Fundación Conde de Valenciana as lead sponsor.Synced 14 Nov 2026
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany
Compiled from ClinicalTrials.gov and CTIS registry records · Synced · Editorial standards
At a glance
Instituto de Oftalmología Fundación Conde de Valenciana is the lead sponsor of 12 current clinical trials
in our Mexico register.
6 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Infliximab. The most-studied condition is Conjunctivitis, Allergic.
ClinicalTrials.gov trials by status
Recruiting650%
Not yet open217%
Active, closed433%
Trials by phase
Observational542%
Phase 4325%
Not applicable325%
Phase 218%
01
Clinical trials sponsored by Instituto de Oftalmología Fundación Conde de Valenciana
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
02
Drugs in Instituto de Oftalmología Fundación Conde de Valenciana trials
1 compound
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
A trial with sites in more than one country appears in each of those registers.
05
Questions about Instituto de Oftalmología Fundación Conde de Valenciana trials
How many clinical trials does Instituto de Oftalmología Fundación Conde de Valenciana sponsor?
Instituto de Oftalmología Fundación Conde de Valenciana is the lead sponsor of 12 current trials on ClinicalTrials.gov in our Mexico register, as of the registry sync on 14 November 2026. Completed and withdrawn studies are not counted.
Are Instituto de Oftalmología Fundación Conde de Valenciana trials recruiting?
Yes. 6 of its 12 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is Instituto de Oftalmología Fundación Conde de Valenciana testing?
Its current trials name 1 drug or biological as interventions. The most frequent are Infliximab (1). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 14 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.
Please verify before you rely on this.
This page is general information for life-science and pharmaceutical professionals. It is
not medical advice, and it has not been reviewed by a clinician — our editorial
team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most
recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC)
and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not
automatically interchangeable, and approvals, brand names and indications differ between the US, the
EU/Ireland (EMA/HPRA) and other regions.
Spotted an error? Tell us — we correct promptly and log it.
We value your privacy
With your consent, we use analytics cookies (Google Analytics and Microsoft Clarity) to understand how the site is used and improve it. We do not show advertising. You can change your choice at any time.
